JP2022512830A5 - - Google Patents

Info

Publication number
JP2022512830A5
JP2022512830A5 JP2021523064A JP2021523064A JP2022512830A5 JP 2022512830 A5 JP2022512830 A5 JP 2022512830A5 JP 2021523064 A JP2021523064 A JP 2021523064A JP 2021523064 A JP2021523064 A JP 2021523064A JP 2022512830 A5 JP2022512830 A5 JP 2022512830A5
Authority
JP
Japan
Application number
JP2021523064A
Other languages
Japanese (ja)
Other versions
JPWO2020084115A5 (https=
JP7629400B2 (ja
JP2022512830A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/079188 external-priority patent/WO2020084115A1/en
Publication of JP2022512830A publication Critical patent/JP2022512830A/ja
Publication of JPWO2020084115A5 publication Critical patent/JPWO2020084115A5/ja
Publication of JP2022512830A5 publication Critical patent/JP2022512830A5/ja
Application granted granted Critical
Publication of JP7629400B2 publication Critical patent/JP7629400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523064A 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体 Active JP7629400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382759.1 2018-10-25
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (4)

Publication Number Publication Date
JP2022512830A JP2022512830A (ja) 2022-02-07
JPWO2020084115A5 JPWO2020084115A5 (https=) 2024-03-21
JP2022512830A5 true JP2022512830A5 (https=) 2024-03-21
JP7629400B2 JP7629400B2 (ja) 2025-02-13

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523064A Active JP7629400B2 (ja) 2018-10-25 2019-10-25 エクテナサイジン誘導体を含む薬物抗体複合体

Country Status (37)

Country Link
US (1) US20230012681A1 (https=)
EP (1) EP3870234B1 (https=)
JP (1) JP7629400B2 (https=)
KR (1) KR20210086669A (https=)
CN (1) CN113226377B (https=)
AR (1) AR117657A1 (https=)
AU (1) AU2019368687B2 (https=)
BR (1) BR112021007718A2 (https=)
CA (1) CA3117268C (https=)
CL (1) CL2021001039A1 (https=)
CO (1) CO2021006838A2 (https=)
DK (1) DK3870234T3 (https=)
EA (1) EA202191131A1 (https=)
EC (1) ECSP21035414A (https=)
ES (1) ES2939494T3 (https=)
FI (1) FI3870234T3 (https=)
HR (1) HRP20230275T1 (https=)
HU (1) HUE061606T2 (https=)
IL (1) IL282577B2 (https=)
JO (1) JOP20210083B1 (https=)
LT (1) LT3870234T (https=)
MA (1) MA59661B1 (https=)
MD (1) MD3870234T2 (https=)
MX (1) MX2021004746A (https=)
MY (1) MY206221A (https=)
PH (1) PH12021550930A1 (https=)
PL (1) PL3870234T3 (https=)
PT (1) PT3870234T (https=)
RS (1) RS64068B1 (https=)
SA (1) SA521421855B1 (https=)
SG (1) SG11202104154WA (https=)
SI (1) SI3870234T1 (https=)
SM (1) SMT202300076T1 (https=)
TW (1) TWI824043B (https=)
UA (1) UA129803C2 (https=)
WO (1) WO2020084115A1 (https=)
ZA (1) ZA202103478B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
TW202313039A (zh) * 2021-05-19 2023-04-01 西班牙商瑪製藥股份有限公司 Pm14用途與方案
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
CN120417935A (zh) * 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
WO2024155565A2 (en) * 2023-01-17 2024-07-25 Yarrow Therapeutics, Inc. Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
CN118878690B (zh) * 2023-11-28 2026-01-09 南京大学 一种抗地高辛纳米抗体的制备及其应用
WO2025228595A1 (en) * 2024-04-30 2025-11-06 Pharma Mar, S.A. Use of compound ia in the treatment of cancers including combination therapy with atezolizumab.
TW202547488A (zh) * 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之化合物Ia和拓樸異構酶I抑制劑的組合
WO2025233522A1 (en) * 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
AR054181A1 (es) * 2004-08-26 2007-06-06 Nicholas Piramal India Ltd Prodrogas que contienen enlaces bio-divisibles. composiiciones farmaceuticas
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
HRP20231233T1 (hr) * 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
KR20230004714A (ko) * 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
JP2022512830A5 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112019016142A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021015080A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)